Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer
December 10 2018 - 12:00AM
Business Wire
-- Mr. O’Day Brings Global Pharmaceutical
Leadership Experience Across Geographies and Therapeutic
Areas --
-- Appointment Effective March 1, 2019
--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its
Board of Directors has named Daniel O’Day Chairman of the Board and
Chief Executive Officer, effective March 1, 2019. Mr. O’Day is
currently the CEO of Roche Pharmaceuticals. He has held the
position since 2012, and prior to that led Roche Diagnostics. His
career spans three decades of diverse leadership roles across North
America, Asia Pacific and Europe.
The Board has also appointed Gregg Alton as interim Chief
Executive Officer for the period of January 1, 2019 until Mr.
O’Day’s start date of March 1, 2019. Mr. Alton has held a number of
executive positions at Gilead over the past 20 years, with
experience in legal, medical affairs, policy and commercial. He
previously served as general counsel and in August of this year,
was appointed Chief Patient Officer.
“Following a comprehensive search, the Board became convinced
that Dan is the right leader to bring Gilead into the future,” said
John C. Martin, PhD, Chairman, Gilead Sciences Board of Directors.
“He is uniquely qualified to take on this role given his track
record of success in highly scientific and competitive therapeutic
areas, deep understanding of the evolving healthcare environment
around the world, and unwavering commitment to driving innovation
across all aspects of a business, which will serve Gilead and our
stakeholders well. Additionally, Dan brings expertise and values
that are aligned with our organization, and I, along with Gilead’s
entire Board, am confident in his ability to work alongside our
talented leadership team and deliver on our ambitious goals.”
After joining Roche Pharmaceuticals in 1987, Mr. O’Day held
various positions in the United States before moving to Roche
headquarters in Switzerland in 1998. During his time in
Switzerland, he held leadership roles in Global Marketing and
Lifecycle Management. In 2001, he moved to Tokyo to become Head of
Corporate Planning for Roche Pharmaceuticals in Japan and later
moved to Denmark to serve as General Manager. He became President
of Roche Molecular Diagnostics in California in 2006 and
subsequently returned to Roche headquarters to lead the Diagnostics
Division before assuming his current position. He is a member of
the corporate executive committee of F. Hoffmann La Roche AG and a
member of the boards of Shanghai Roche Pharmaceuticals Ltd., Roche
(China) Holding, Roche Pharma Schweiz AG, Genentech, Inc., Chugai
Pharmaceuticals Co., Ltd., Flatiron Health, Inc., and Foundation
Medicine, Inc. Additionally, he has served as a member of the board
of the European Federation of Pharmaceutical Industries and
Associations. Mr. O’Day holds a Bachelor of Science in Biology from
Georgetown University in Washington, D.C. and an MBA from the
Columbia Business School at Columbia University in New York.
“I have long admired Gilead for its work to develop medicines
that have fundamentally changed the way HIV and viral hepatitis are
treated. The company has successfully grown into a global
organization, providing access to people around the world, while
maintaining its focus on innovative science,” said Mr. O’Day.
“Together with the Board, leadership team and Gilead’s 11,000
employees, I look forward to building on this in ways that I
believe will – in keeping with Gilead’s mission – transform the
lives of millions of individuals.”
As previously announced, Dr. Martin will step down from the
company’s Board of Directors, effective March 1, 2019, Mr. O’Day’s
first day of employment. Also as previously announced, John F.
Milligan, PhD, will step down from his role as President and Chief
Executive Officer and as a member of the Board at the end of
2018.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information about Gilead at
www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181209005030/en/
Sung Lee, Investors(650) 524-7792
Amy Flood, Media(650) 522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024